Department of Biochemistry & Molecular Biology, New Jersey Medical School, and New Jersey Medical School-University Hospital Cancer Center, UMDNJ, Newark, New Jersey, USA.
PLoS One. 2013;8(1):e54487. doi: 10.1371/journal.pone.0054487. Epub 2013 Jan 18.
Polymorphisms in the interferon regulatory factor 5 (IRF5) gene have been consistently replicated and shown to confer risk for or protection from the development of systemic lupus erythematosus (SLE). IRF5 expression is significantly upregulated in SLE patients and upregulation associates with IRF5-SLE risk haplotypes. IRF5 alternative splicing has also been shown to be elevated in SLE patients. Given that human IRF5 exists as multiple alternatively spliced transcripts with distinct function(s), it is important to determine whether the IRF5 transcript profile expressed in healthy donor immune cells is different from that expressed in SLE patients. Moreover, it is not currently known whether an IRF5-SLE risk haplotype defines the profile of IRF5 transcripts expressed. Using standard molecular cloning techniques, we identified and isolated 14 new differentially spliced IRF5 transcript variants from purified monocytes of healthy donors and SLE patients to generate an IRF5 variant transcriptome. Next-generation sequencing was then used to perform in-depth and quantitative analysis of full-length IRF5 transcript expression in primary immune cells of SLE patients and healthy donors by next-generation sequencing. Evidence for additional alternatively spliced transcripts was obtained from de novo junction discovery. Data from these studies support the overall complexity of IRF5 alternative splicing in SLE. Results from next-generation sequencing correlated with cloning and gave similar abundance rankings in SLE patients thus supporting the use of this new technology for in-depth single gene transcript profiling. Results from this study provide the first proof that 1) SLE patients express an IRF5 transcript signature that is distinct from healthy donors, 2) an IRF5-SLE risk haplotype defines the top four most abundant IRF5 transcripts expressed in SLE patients, and 3) an IRF5 transcript signature enables clustering of SLE patients with the H2 risk haplotype.
干扰素调节因子 5(IRF5)基因中的多态性已被反复证实与系统性红斑狼疮(SLE)的发生风险或保护有关。SLE 患者的 IRF5 表达显著上调,上调与 IRF5-SLE 风险单倍型相关。IRF5 的可变剪接也在 SLE 患者中升高。鉴于人类 IRF5 存在多种具有不同功能的可变剪接转录本,因此确定健康供体免疫细胞中表达的 IRF5 转录本谱是否与 SLE 患者不同非常重要。此外,目前尚不清楚 IRF5-SLE 风险单倍型是否定义了表达的 IRF5 转录本谱。我们使用标准的分子克隆技术,从健康供体和 SLE 患者的纯化单核细胞中鉴定和分离了 14 种新的差异剪接 IRF5 转录本变体,以生成 IRF5 变体转录组。然后使用下一代测序对 SLE 患者和健康供体的原发性免疫细胞中的全长 IRF5 转录本表达进行深度和定量分析。从头发现新的剪接连接获得了额外可变剪接转录本的证据。这些研究的数据支持 SLE 中 IRF5 可变剪接的整体复杂性。下一代测序的结果与克隆相关,并在 SLE 患者中给出了类似的丰度排名,从而支持使用这项新技术进行深入的单基因转录谱分析。这项研究的结果首次证明:1)SLE 患者表达的 IRF5 转录本谱与健康供体不同;2)IRF5-SLE 风险单倍型定义了 SLE 患者中表达最多的前四个 IRF5 转录本;3)IRF5 转录本谱能够将具有 H2 风险单倍型的 SLE 患者聚类。